PCSK9 Controls Where Pancreatic Cancer Spreads by Regulating Cholesterol
A landmark Nature study reveals PCSK9 levels in pancreatic cancer cells dictate whether tumors metastasize to the liver or lungs via cholesterol metabolism.
Summary
Researchers discovered that PCSK9, a protein best known for regulating cholesterol, acts as a master switch determining whether pancreatic ductal adenocarcinoma (PDAC) cells preferentially colonize the liver or lungs. Low-PCSK9 tumor cells maintain high LDL receptors, avidly absorb cholesterol-rich LDL from liver tissue to fuel mTORC1-driven growth, and remodel the hepatic microenvironment. High-PCSK9 lung-avid cells instead synthesize their own cholesterol intermediates—particularly 7-dehydrocholesterol—that protect against ferroptosis, a cell-death vulnerability in the oxygen-rich lung. Manipulating PCSK9 experimentally redirected metastases between organs, establishing it as both necessary and sufficient for organ site preference. Patient tumor specimens confirmed these patterns clinically.
Detailed Summary
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, largely because it metastasizes early and aggressively. Where it spreads matters clinically: patients with lung-only metastases survive significantly longer than those with liver or multi-site disease. Yet the molecular drivers of this organ preference have remained poorly understood—until now.
Using publicly available high-throughput in vivo metastasis screen data (MetMap) covering 25 PDAC cell lines across five organs, the researchers identified two reproducible clusters: one strongly liver-avid (C1-Liver) and one lung-avid (C2-Lung). Importantly, all four experimentally validated cell lines shared identical KRAS, CDKN2A, and TP53 mutations, ruling out canonical oncogenic drivers as the explanation. Gene expression correlation analysis then pinpointed PCSK9 as the top transcript distinguishing the two clusters—high in lung-avid, low in liver-avid lines.
PCSK9 is a serine protease that degrades the LDL receptor (LDLR), suppressing cellular LDL-cholesterol import. C1-Liver (PCSK9-low) cells maintain abundant LDLR, avidly take up LDL from the cholesterol-rich hepatic environment, accumulate lysosomal cholesterol, and activate mTORC1 to drive proliferation. They also convert LDL-derived cholesterol into the oxysterol 24(S)-hydroxycholesterol, which reprograms neighboring hepatocytes to release nutrients, effectively hijacking the liver niche. Blocking LDLR in these cells—either genetically or by depleting lipoproteins—impairs their liver colonization, confirming LDL dependence.
Conversely, C2-Lung (PCSK9-high) cells cannot efficiently import LDL. Instead, they upregulate the distal cholesterol biosynthesis pathway, generating intermediates such as 7-dehydrocholesterol (7-DHC) and 7-dehydrodesmosterol. These molecules confer resistance to ferroptosis—an iron-dependent oxidative cell death particularly threatening in the oxygen-rich lung microenvironment. Inhibiting this synthetic pathway with the DHCR7 inhibitor AY9944 selectively killed lung-avid cells and suppressed lung metastases in vivo.
Critically, PCSK9 was shown to be both necessary and sufficient for organ site selection: overexpressing PCSK9 in liver-avid KP4 cells redirected them to the lung, while CRISPR knockout of PCSK9 in lung-avid HPAC cells drove colonization of the liver instead. Human patient data corroborated these findings: primary tumors from patients who later developed liver metastases showed low PCSK9 and high LDLR by immunohistochemistry, while those who developed lung metastases showed the opposite pattern. Single-cell RNA sequencing of matched primary and metastatic specimens further validated the relationship. These findings establish a PCSK9-driven cholesterol axis as a clinically relevant, potentially actionable determinant of PDAC metastatic organ tropism.
Key Findings
- PCSK9 expression level in primary PDAC predicts whether metastases form in the liver (low PCSK9) or lungs (high PCSK9).
- Liver-avid PDAC cells use LDLR-mediated LDL uptake to activate lysosomal mTORC1 and remodel the hepatic microenvironment via oxysterol signaling.
- Lung-avid PDAC cells upregulate distal cholesterol synthesis (7-DHC, 7-dehydrodesmosterol) to resist ferroptosis in the oxygen-rich lung.
- Experimentally raising or lowering PCSK9 was sufficient to redirect metastases between liver and lung in mouse models.
- Matched patient tumor specimens confirmed PCSK9/LDLR expression patterns correlate with subsequent metastatic site in humans.
Methodology
The study combined public MetMap in vivo screen data (25 PDAC lines, 5 organs) with intrasplenic, tail vein, and intracardiac mouse injection models, CRISPR knockouts, 3D light-sheet microscopy, flow cytometry, lipidomics, and immunohistochemistry of matched primary-to-metastasis human PDAC cohorts. Single-cell RNA sequencing of primary and liver-metastatic patient specimens provided additional transcriptomic validation.
Study Limitations
Most mechanistic experiments relied on a small number of human cell lines and mouse xenograft or syngeneic models, which may not fully recapitulate the complexity of human metastasis. The matched patient cohort used for IHC validation was limited in size, and causality in humans remains correlative. The contribution of systemic cholesterol levels (e.g., from diet or statin use) to PCSK9-driven organ tropism in patients was not directly examined.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.